Offers liquid, lyophilized, and complex injectable formulation development, compatibility and stability studies, and clinical-to-commercial sterile manufacturing for small molecules and biologics.
Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Offers liquid, lyophilized, and complex injectable formulation development, compatibility and stability studies, and clinical-to-commercial sterile manufacturing for small molecules and biologics.
The website lists polymorph, hydrate, solvate, salt, cocrystal, ASD, and difficult-to-crystallize material screening.
Services include single-crystal growth, SCXRD, and structure determination from XRPD; these disclosures do not establish MicroED availability.
Biologics analytical testing, bioassays and stability
Integrated CRO/CDMO analytical services
Program / service
Target / indication
Representative stage
Evidence & scope
Formulation development capabilities
Defined by the client project · Defined by the client project
Services / platform
Service capability does not establish efficacy in humans
Solid-state R&D capabilities
Determined by the submitted sample and research question · Not applicable; service capability
Services / platform
Not applicable; not a human clinical program
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Communications Chemistry study reports RaPiD-mAb-MS, combining plate-based preparation with direct-infusion mass spectrometry for antibody peptide mapping. The original abstract describes analysis of 96 samples in about 1.5–2 hours, routinely exceeding 95% sequence coverage, across 28 antibodies and more than 2,000 samples. The reported comparisons cover several modifications and sequence variants; broader method suitability still requires evaluation.
A Nature Communications study reports a peptide–oligonucleotide nanohybrid for bone-targeted miR-26a-5p delivery. The original abstract describes reduced GSK-3β expression and stabilization of HIF-1α, supporting coupled bone formation and angiogenesis. Systemic administration limited skeletal and vascular injury in a rat glucocorticoid-induced bone-loss model. This is preclinical miRNA delivery, not oral cyclic peptide therapy or human efficacy evidence.
FDA granted accelerated approval to amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma after platinum chemotherapy and an anti-PD-(L)1 antibody. HPV-associated oropharyngeal cancer is excluded. In the 102-patient OrigAMI-4 efficacy population, response rate was 42%. Continued approval requires confirmatory clinical benefit; this is not traditional full approval.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Execution sites, current equipment capacity, technology transfer, and the available scope of GMP services require confirmation.
Public sources confirm service availability. Sample suitability, scope of work, pricing, turnaround time, success criteria, and the quality system require direct confirmation.
This record describes service capabilities, not the clinical progress of a drug candidate or an independent validation of service success rates.
Service-provider record; no proprietary drug pipeline implied. Confirm laboratory qualification and project suitability.
